L esions of the airway epithelium are frequently observed in asthma patients. Therefore, inflammatory mediators such as chemokines or cytokines may influence airway remodeling. Among these cytokines, interleukin (IL)-13 recently has emerged as a pivotal molecule with which to promote airway hyperresponsiveness. 1 We have investigated the effect of IL-13 on the mucociliary differentiation of human nasal epithelial cells in primary culture. IL-13 alters ciliated cell differentiation and, in parallel, largely increases the proportion of secretory cells in a dose-dependent and time-dependent manner, and impairs lateral cell contacts. Treatment with IL-13 and increasing amounts of an IL-4 mutant (Y124D), which is a selective antagonist of the IL-4/IL-13 shared receptor, abolishes the effects of IL-13. 2 Using differential screening of treated and nontreated epithelial cells during differentiation, we showed that transforming growth factor-␤1 gene expression is increased in the presence of the cytokine, reinforcing the idea that IL-13 could induce tissue fibrosis by selectively activating transforming growth factor-␤1, as was recently shown in mice. 3 Because multiple IL-13 effects contribute to the asthma phenotype, inhibiting the cytokine or its receptors in vivo may be relevant in patients with chronic lung diseases such as asthma. Abbreviation: IL ϭ interleukin T he cellular events underlying the development and maintenance of allergic airway disease are complex. A number of different inflammatory cell types, including lymphocytes, mast cells, and eosinophils, are thought to play key roles in allergic airway disease. The accumulation of eosinophils in the airway is one of the hallmarks of asthma, and a large body of work has focused on understanding the biology of eosinophils in patients with asthma. Interleukin (IL)-5 is a crucial factor in the biology of eosinophils and has been shown to regulate a number of eosinophil functions, including apoptosis, chemotaxis, and exocytosis. In order to identify genes and proteins that are regulated by IL-5, we have performed proteomic and genomic analyses of human eosinophils that had and had not been treated with IL-5. In one set of experiments, eosinophils were prepared from the peripheral blood of five healthy donors and were stimulated in vitro with IL-5 or vehicle. Protein extracts were resolved on two-dimensional gels, and differentially expressed proteins were excised, trypsinized, and identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. In parallel experiments, microarrays (U95A; Affymetrix; Santa Clara, CA) were run on pooled RNA from primary human eosinophils that had and had not been treated with IL-5. Genes expressed in nonstimulated eosinophils were identified, as were subsets of genes that had been either up-regulated or downregulated by IL-5 treatment. The results from the genomics analysis were compared with the results from the proteomics analysis. Abbreviation: TNF ϭ tumor necrosis factor G enetic polymorphisms influence the magnitude of the cytokine response after the occurrence of various inflammatory stimuli. The pathophysiology of asthma involves, in part, the inflammation of the airway epithelium. Tumor necrosis factor (TNF)-␣, a proinflammatory cytokine, is released into the airway and serum of patients with asthma. Indeed, higher serum levels of TNF-␣ have been demonstrated in children with active disease. We tested the hypothesis that children with asthma have genetic polymorphisms in the regulatory region of the gene coding for TNF-␣ that are associated with higher levels of TNF-␣.
Lack of Association

Materials and Methods
Blood samples were obtained from children with exacerbations of asthma. Genotypes were determined by polymerase chain reaction amplification and restriction enzyme digestion. Genotypic frequencies were determined and compared with samples from healthy control subjects (Table 1) . Statistical analysis was performed using 2 analysis.
Results
Thirty-eight children with asthma were enrolled into the study. The genotypic frequencies of the polymorphic
